However, a combination of MYCN amplification with acquired drug resistance in recurrent NB tumors results in a major shift in responsiveness to several families of chemotherapeutics, including topoisomerase I inhibitors [44,48]. This evidence concerns the gene MYCN and neuroblastoma.